Sign In
Buy GLYC
$15.71
+0 (+0%)
At Close: Oct 01, 2025
Stocks To Watch: Nike, Apple, Ford And Stressed Banks
08:39am, Saturday, 20'th Jun 2020
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th
Bajaj Allianz Life insurance launches child education plan with guaranteed income – Check key features
07:20pm, Thursday, 18'th Jun 2020
This new-age guaranteed income life insurance plan comes with unique features like the flexibility to receive or accumulate Survival Benefits including Cash Bonus.
Federated Hermes Inc. Boosts Position in GlycoMimetics Inc (NASDAQ:GLYC)
07:54am, Tuesday, 16'th Jun 2020
Federated Hermes Inc. boosted its position in shares of GlycoMimetics Inc (NASDAQ:GLYC) by 222.6% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. Th
Zacks Investment Research Upgrades GlycoMimetics (NASDAQ:GLYC) to Buy
03:52am, Sunday, 14'th Jun 2020
GlycoMimetics (NASDAQ:GLYC) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Friday, Zacks.com reports.
Beaumont Hospital extends deadline for opt-outs to genomics research
05:56pm, Friday, 12'th Jun 2020
Study aims to harvest information on brain tumours from 9,000 Irish patients, many of whom are dead
New Efficacy and Biomarker Data From Rivipansel Phase 3 RESET Trial to Be Presented at Sickle Cell Meeting
04:23pm, Friday, 12'th Jun 2020
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that a post hoc analysis of the Phase 3 RESET study evaluating the efficacy of rivipansel , its wholly-owned development candidate, in acute vaso-occ
How GlycoMimetics (GLYC) Stock Stands Out in a Strong Industry
12:41pm, Friday, 12'th Jun 2020
GlycoMimetics (GLYC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
New Efficacy and Biomarker Data From Rivipansel Phase 3 RESET Trial to Be Presented at Sickle Cell Meeting
12:00am, Friday, 12'th Jun 2020
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that a post hoc analysis of the Phase 3 RESET study evaluating the efficacy of rivipansel , its who
Next government needs to create a national public genome project
05:00am, Thursday, 11'th Jun 2020
Net Results: There is a lack of transparency over consent for usage of brain tissue DNA
Bitcoin: Speculate Like Tudor And Hold It Like Buffett (Cryptocurrency:BTC-USD)
08:00pm, Monday, 08'th Jun 2020
Legendary macro investor Paul Tudor Jones recently made a strong argument for bitcoin to seek refuge from the Great Monetary Inflation (GMI). But most investors
Risk Premia Forecasts: Major Asset Classes 2 June 2020
07:29am, Wednesday, 03'rd Jun 2020
Long-term forecast for the Global Market Index’s risk premia ticked higher in May, rising for a second month after a run of declines earlier in the year. No one
Major Asset Classes: May 2020 Performance Review
06:20am, Tuesday, 02'nd Jun 2020
Asset prices continued to rebound in May, building on April’s widespread gains. Commodities joined the party this time by leading the across-the-board celebrat
Oil And Stocks Sizzled In May, But Cash And Bonds Are King So Far In 2020
12:00am, Monday, 01'st Jun 2020
Market Overview Analysis by James Picerno covering: Crude Oil WTI Futures, Vanguard Russell 3000 Index Fund ETF Shares, Bloomberg Commodity TR. Read James Picerno's latest article on Investing.com
GlycoMimetics to Present at Upcoming Jefferies Virtual Healthcare Conference
01:00pm, Friday, 29'th May 2020
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Chief Executive Officer Rachel King will provide a company overview at the upcoming Jefferies Virtual Healthcare Conference. The presentation wi
Global Sickle Cell Disease Clinical Trial Pipeline Highlights 2020 - ResearchAndMarkets.com
12:00am, Friday, 29'th May 2020
The
